Turn Therapeutics Inc

Global Health Solutions Inc, based in Westlake Village, CA, is a pioneering company that specializes in innovative drug delivery technology. Their patented PermaFusion Technology revolutionizes topical delivery by permanently suspending liquid nanodroplets containing biologically active ingredients within petrolatum carriers, without the need for additional emulsifiers or binding agents. This groundbreaking technology maximizes effectiveness while minimizing risk, allowing for the use of less active ingredient without compromising efficacy, reducing toxicity, irritation, and sensitization. With a focus on innovation and education, Global Health Solutions Inc aims to render disease obsolete. Their team of experts has developed therapeutic targets based on years of real-world evidence, resulting in a range of lead programs that address various medical conditions. Through their commitment to scientific research and development, Global Health Solutions Inc is leading a revolution in drug delivery technology, offering a promising solution for improved patient outcomes.Generated from the website

Arcutis Biotherapeutics, Inc., based in Westlake Village, CA, is dedicated to advancing meaningful innovation in medical dermatology, particularly in the treatment of immune-mediated skin diseases. Founded in 2016, the company leverages extensive dermatology expertise and a deep understanding of patient and healthcare professional needs to develop novel therapies that address urgent unmet challenges in chronic inflammatory skin conditions. With a robust pipeline that includes topical formulations like ZORYVE roflumilast cream, Arcutis is committed to simplifying disease management and improving patient outcomes. The company's leadership team comprises seasoned professionals with a track record of multiple FDA-approved products, positioning Arcutis as a significant player in the dermatology field. Generated from the website

ACELRYIN, Inc is a late stage clinical biopharma company based in Agoura Hills, CA, focused on accelerating the development and delivery of transformative medicines for patients. Led by a team of veteran biopharma executives, they are actively investigating the potential of izokibeplonigutamab in diseases where differentiated inhibition of validated targets may help address unmet patient needs. With a corporate culture of courageous caring and a commitment to placing patients first, ACELYRIN is dedicated to investing in, developing, and commercializing clinically meaningful therapies. Their pipeline includes promising treatments such as lonigutamab, with recent positive proof of concept data demonstrating rapid improvements for patients. Generated from the website